NASDAQ:ACERAcer Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acer Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range$3.11MA: $3.48▼$4.4752-Week Range N/AVolume3.02 million shsAverage Volume370,560 shsMarket Capitalization$55.45 millionP/E RatioN/ADividend YieldN/ABeta1.82 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. The company was founded in 2013 and is headquartered in Newton, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAcer Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Acer Therapeutics has a potential upside of ∞ from its current price of $0.00.Amount of Analyst CoverageAcer Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAcer Therapeutics has received 282 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAcer Therapeutics has received 238 “underperform” votes. (Add your “underperform” vote.)Community SentimentAcer Therapeutics has received 54.23% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote “Outperform” if you believe ACER will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAcer Therapeutics does not currently pay a dividend.Dividend GrowthAcer Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acer Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $707,497.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 20.10% of the stock of Acer Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.45% of the stock of Acer Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acer Therapeutics are expected to grow in the coming year, from ($1.38) to ($1.21) per share. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.93 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACER Previous Symbol CUSIPN/A CIK1069308 Webwww.acertx.com Phone844-902-6100Debt Debt-to-Equity RatioN/A Current Ratio4.29 Quick Ratio4.29Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.82 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($2.91) Net Income$-29,420,000.00 Net MarginsN/A Return on Equity-127.41% Return on Assets-110.05%Miscellaneous Employees23 Outstanding Shares10,250,000Market Cap$55.45 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable 30 days | 90 days | 365 days | Advanced Chart Receive ACER News and Ratings via Email Sign-up to receive the latest news and ratings for ACER and its competitors with MarketBeat's FREE daily newsletter. Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Acer Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Acer Therapeutics. When is Acer Therapeutics' next earnings date? Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Acer Therapeutics. How were Acer Therapeutics' earnings last quarter? Acer Therapeutics Inc (NASDAQ:ACER) announced its earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.09. View Acer Therapeutics' earnings history. What price target have analysts set for ACER? 3 analysts have issued 12 month target prices for Acer Therapeutics' shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Acer Therapeutics' share price to reach $10.00 in the next twelve months. View analysts' price targets for Acer Therapeutics. Has Acer Therapeutics been receiving favorable news coverage? Media stories about ACER stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Acer Therapeutics earned a media sentiment score of -4.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Acer Therapeutics. Are investors shorting Acer Therapeutics? Acer Therapeutics saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 350,300 shares, a decline of 7.5% from the July 15th total of 378,800 shares. Based on an average daily trading volume, of 270,600 shares, the days-to-cover ratio is currently 1.3 days. Currently, 6.8% of the shares of the company are short sold. View Acer Therapeutics' Short Interest. Who are some of Acer Therapeutics' key competitors? Some companies that are related to Acer Therapeutics include Marinus Pharmaceuticals (MRNS), Strongbridge Biopharma (SBBP), Aldeyra Therapeutics (ALDX), Aquestive Therapeutics (AQST), Chimerix (CMRX), Nature's Sunshine Products (NATR), Aduro BioTech (ADRO), Kalvista Pharmaceuticals (KALV), Five Prime Therapeutics (FPRX), Chiasma (CHMA), NuCana (NCNA), Galera Therapeutics (GRTX), Paratek Pharmaceuticals (PRTK), Lexicon Pharmaceuticals (LXRX) and Alpine Immune Sciences (ALPN). View all competitors. What other stocks do shareholders of Acer Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Sarepta Therapeutics (SRPT), Amarin (AMRN), Anavex Life Sciences (AVXL), NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Advanced Micro Devices (AMD), Arena Pharmaceuticals (ARNA), Crispr Therapeutics (CRSP) and Madrigal Pharmaceuticals (MDGL). Who are Acer Therapeutics' key executives? Acer Therapeutics' management team includes the following people: Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 43)Mr. Harry S. Palmin, COO & CFO (Age 49)Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 54)Mr. Donald R. Joseph, Chief Legal Officer & Sec. (Age 65)Ms. Jeannie Kim, VP of Corp. Devel. What is Acer Therapeutics' stock symbol? Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER." How do I buy shares of Acer Therapeutics? Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. How big of a company is Acer Therapeutics? Acer Therapeutics has a market capitalization of $0.00. The biopharmaceutical company earns $-29,420,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe. What is Acer Therapeutics' official website? The official website for Acer Therapeutics is www.acertx.com. How can I contact Acer Therapeutics? Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected] This page was last updated on 8/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
